Study of the Interactions Between Dientamoba Fragilis and the Gut Microbiota
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Strasbourg, France, 67091
- Laboratoire de Parasitologie et de Mycologie Médicale du Plateau Technique de Microbiologie des Hôpitaux Universitaires de Strasbourg
-
Strasbourg, France, 67091
- Médecine interne, maladies tropicales et infectieuses Hôpital Civil
-
Strasbourg, France, 67091
- Service de Médecine Interne - Diabète et Maladies métaboliques Hôpital Civil
-
Strasbourg, France, 67098
- Service d'hépato gastro-entérologie et assistance nutritive Hôpital Hautepierre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria for symptomatic group:
- male/female aged at least of 18 years
- subject with abdominal pain, diarrhea, bloating
- no other known intestinal disease
Inclusion Criteria for asymptomatic group:
- male/female aged at least of 18 years
- no known intestinal disease
Exclusion Criteria of symptomatic and asymptomatic groups:
- chronic intestinal diseases such as IBD, IBS …
- intake of antibiotic or probiotic within the 2 last months
- subject in exclusion period
- subject unable to understand information for a free consent to the study
- subject in safeguarding justice or guardianship
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Symptomatic subjects
Subjects with intestinal symptoms
|
|
|
Asymptomatic subjects
Subjects without intestinal symptoms
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
16SrRNA copy numbers
Time Frame: Within the 2 days following inclusion
|
Within the 2 days following inclusion
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: CANDOLFI Ermanno, MD, Hopitaux Universitaires de Strasbourg
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 6110
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.